Verition Fund Management
LAB icon

Verition Fund Management’s Standard BioTools LAB Stock Holding History

Verition Fund Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-230,523
Closed -$904K – 2884
2021
Q4 		$904K Buy
+230,523
New +$1.08M 0.01% 1358

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's LAB Position: Q1 2022 in Review

Verition Fund Management sold out of Standard BioTools (LAB) in Q1 2022, closing a stake of 230,523 shares — an estimated $904K sold.

Verition Fund Management first reported a position in LAB in Q4 2021 and held it in 1 quarter. The position peaked at $904K in Q4 2021. 109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

  • Verition Fund Management reported no remaining Standard BioTools position as of Q1 2022 after selling out during the quarter.
  • Verition Fund Management sold 230,523 Standard BioTools shares in Q1 2022, an estimated $904K.
  • Verition Fund Management first reported a position in Standard BioTools in Q4 2021 and held it in 1 quarter.
  • Verition Fund Management's Standard BioTools position peaked at $904K in Q4 2021.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on Verition Fund Management's 13F filing for Q1 2022, filed 13 May 2022.